FDA warning letters October 2026: all 18 drug and device CGMP letters

The October 2026 FDA warning letters are the 18 drug and device CGMP and quality system letters that FDA posted to its warning letter index on October 6, 13, 20 and 27, 2026. Fifteen went to drug makers, compounders, a testing lab and a PET producer; three went to device makers. This tracker lists each one with its letter number, issue date and posting date, then matches every inspected recipient to its Form 483 record in Atlas (release of August 15, 2026).

Key facts:

• FDA posted 56 warning letters in October 2026; 18 of them cite drug CGMP (21 CFR 210, 211, 212) or device quality system requirements.
• Eleven of the 18 letters are dated in October; seven are dated in August or September, and the median gap from signature to posting was 16.5 days.
• 21 CFR 211.22, quality unit responsibilities, appears on 10 of the 13 letters that cite part 211, and 21 CFR 211.192, investigations, appears on 7.
• Five recipients, all outside the US, were already on Import Alert 66-40 when FDA signed their letters.
• Atlas holds an inspection record for 15 of the 18 recipients; the other three were never inspected and received letters based on records FDA requested under section 704(a)(4).

How many FDA warning letters were posted in October 2026?

FDA posted 18 drug and device CGMP or QSR warning letters in October 2026, out of 56 letters posted in total. The other 38 covered foods, tobacco, animal drugs, unlicensed biologics, unapproved drug claims, a GLP laboratory, device premarket and reporting violations, and drug promotion. The table below lists the 18, in posting order.

Two names from early trade coverage are absent. Empower Pharmacy's September 18 letter (WL 738238) was posted before October, and we found no Reliance Life Sciences letter in the October postings. Letters dated late October to Pritam International, Guangdong Bangze Medicine and Conroe Welding Supply were posted on November 3 and belong to next month's list.

FDA posts letters on Tuesdays, so the posting date says nothing about when the problem was found. Pine's letter waited 60 days between signature and posting. TSP, Sanrace and Northland, all signed October 22, appeared five days later.

Which 21 CFR sections did the October 2026 warning letters cite most?

The October 2026 warning letters cited 21 CFR 211.22, the quality unit rule, more than any other section: 10 of the 13 letters that cite part 211 include it. 21 CFR 211.192, investigations of discrepancies and failures, follows on 7. Component identity testing under 211.84(d) and sterile process validation under 211.113(b) each appear on 6.

The right-hand column comes from the FDA Form 483 database in Atlas: the share of 90 recent human-drug Form 483s citing each section (release of August 15, 2026). Warning letters concentrate on fewer sections than 483s do, so the higher percentages are expected. The gap on 211.84(d) is the one to read: identity testing of incoming components shows up on 16% of 483s but on almost half of October's letters, because FDA cites it on OTC makers that release components on a supplier's certificate of analysis without testing them. We counted only numbered violations and left out 211.34, the consultant recommendation FDA adds to most CDER letters. The regulation text is in 21 CFR part 211 on eCFR.

What themes run through the October letters?

Four themes cover most of the month.

Recall pressure appears in five drug letters. FDA recommended recalls to Baxter (July 17), Rohto (July 7), Silgan (July 22) and Signature Formulations (September 15). It tried three times in February 2026 to reach Jiangmen Shuizirun about recalling products labeled sterile and got no reply from the firm or its US agent.

Repeat enforcement is the other thread. Hanlim's letter refers back to warning letter 320-19-01, and Signature Formulations received warning letter 320-26-38 on January 21, 2026, eight months before this one.

Which recipients were already on Import Alert 66-40?

Five October recipients were already on Import Alert 66-40, the detention-without-examination list for drug makers that FDA finds out of CGMP compliance: Jiangmen Shuizirun (since April 20, 2026), Zhejiang Gaorong (July 31), Rohto's Vietnam facility (August 13), TSP Solutions (August 14) and Sanrace (September 21). For these firms the letter documents a decision already in force at the border.

Three of the five, Zhejiang Gaorong, TSP and Sanrace, were never inspected. FDA asked each for records under section 704(a)(4) of the FD&C Act, reviewed what came back, and found enough to cite component testing, release testing and quality unit failures. That is why Atlas holds no facility record for them.

What does the Atlas record show about the October recipients?

Atlas holds an inspection record for 15 of the 18 recipients, and 14 of those records include the Form 483 from the inspection the letter rests on. Unilam's May 2026 inspection postdates the August 15 release. Leaving out Baxter Round Lake's 38-inspection history, the other 14 records hold 50 FDA inspections, and 44 ended with a Form 483.

Seven of the 15 had a warning-letter outcome on record before October: Pine (2015), SCA (2014), Hanlim (2018), SnugZ (2018), Signature Formulations (2017 and 2025), Baxter Round Lake (2015) and Olympus's Hachioji facility (2015 and 2022). Almost half of the inspected recipients had been through warning-letter enforcement before.

The same investigators also turn up across letters. Justin A Boyd, with 279 inspections and 1,374 Form 483 observations on record, inspected Rohto's Vietnam facility from April 6 to 14, 2026 and Hanlim in Yongin from April 16 to 24, both with Hung H Do. Both inspections ended in an October warning letter.

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

What did each October 2026 warning letter say?

TCI BioCosme (Taiwan). FDA inspected the Pingtung County facility March 9 to 13, 2026 and found OTC products released without assay testing of the active ingredient, plus untested components and weak production procedures. The Atlas record shows one inspection, by investigator Khoa Nathan V Tran.

Unilam (South Korea). This UV sunlamp maker is the only October recipient cited under the Quality Management System Regulation, which replaced the old QSR on February 2, 2026. The letter cites ISO 13485:2016 clauses on risk management, design, supplier selection and supplier change notices. Unilam's 2022 Form 483 in Atlas already cited 820.50(b) purchasing data six times.

Pine Pharmaceuticals (New York). The 503B outsourcing facility was inspected November 4 to 14, 2025, with operators failing to sanitize materials before they entered the ISO 5 hood. The Tonawanda site record shows 211.113(b) and 211.192 on the 2021, 2023 and 2024 Form 483s, both of which the letter cites again.

SCA Pharmaceuticals (Arkansas). Every CGMP charge in the September 14 letter was already on the October 2025 Form 483. Our FDA compounding warning letters analysis covers SCA and the 503B citation pattern.

Jiangmen Shuizirun (China). Inspected November 3 to 7, 2025, the firm makes OTC products labeled sterile without procedures to keep them sterile. It did not answer FDA's recall calls and has been on Import Alert 66-40 since April 20, 2026.

Hanlim Pharm (South Korea). FDA saw operators break first air over open sterile tubes. The Hanlim site record holds six inspections and five Form 483s; 211.113(b) appears on the 2018 form, an inspection Atlas records with a warning-letter outcome, and again in 2026.

Silgan Dispensing Systems (Washington). The Spokane facility, Silgan Unicep Packaging, contract-makes non-sterile OTC products. A customer ran a Class I recall for possible fungal contamination, and FDA called the investigation inadequate. The April 2026 Form 483 lists eight observations, starting with 211.192.

Eurofins SF Analytical (Pennsylvania). The Horsham contract lab kept laboratory records without complete data and did not fully investigate discrepancies. Our Eurofins warning letter breakdown traces its two Form 483s.

SnugZ USA (Utah). FDA inspected West Jordan April 27 to May 1, 2026. The SnugZ site record shows 211.192 and 211.160(b) on the 2018, 2021 and 2026 Form 483s, and the 2018 inspection ended in a warning letter.

Baxter, Round Lake (Illinois). Cephalosporin cross-contamination, sterility assurance and a recalled cefazolin lot. Our Baxter warning letter post covers the 38 inspections on record and the four violations.

Zhejiang Gaorong Cosmetic (China). FDA requested records on January 20, 2026 and cited missing component identity testing and a quality unit without authority to reject materials. The firm went on Import Alert 66-40 on July 31.

Signature Formulations (Arizona). FDA sampled the contract manufacturer's drug products after a violative inspection and found every lot contaminated with an undeclared substance that FDA redacted. FDA's earlier inspection had documented shared equipment. The Atlas record shows five inspections, all ending with a Form 483, with warning-letter outcomes in 2017 and 2025.

Olympus Medical Systems (Japan). The letter covers six device facilities in Japan, Germany and Minnesota and cites 12 numbered violations, 11 under the QSR and one under medical device reporting, led by design validation. Our Olympus warning letter post lays out the six Form 483s behind it.

Rohto Pharmaceutical (Vietnam facility). The letter went to Rohto's Osaka headquarters but concerns Rohto-Mentholatum (Vietnam), which makes sterile ophthalmic OTC drugs. FDA found falsified environmental monitoring, personnel monitoring and cleaning records. Rohto recalled all US lots on July 14, 2026. The Ho Chi Minh site record shows five inspections since 2012, every one ending with a Form 483.

Chirp Innovations (Utah). The TENS device maker had no documented procedures for management review, audits, design controls, purchasing, CAPA or complaints. FDA also cites promotion for menstrual pain, outside the K241509 clearance.

TSP Solutions (Singapore). The sunscreen maker answered a September 2025 records request with records that showed no release testing for the identity and strength of each active ingredient. It was placed on Import Alert 66-40 on August 14, 2026.

Sanrace Biotechnology (China). Another records-request letter: no component identity test, no written production procedures and an inadequate quality control unit. Import Alert 66-40 since September 21, 2026.

Northland Nuclear Medicine (North Dakota). The Bismarck PET producer closed CAPAs for recurring low radiochemical yields without effectiveness checks. The Northland site record shows 212.30(b), equipment, on the 2019 and 2023 Form 483s; the letter cites it again.

What should quality teams check after the October letters?

Quality teams should check their own record against the sections FDA cited most this month. Start with three questions:

1. Does each out-of-specification result, rejected batch and visual inspection excursion have a documented investigation that reaches a root cause (211.192)?
2. Does every incoming lot of a high-risk component get a full identity test, rather than release on a supplier certificate (211.84(d))?
3. Has the quality unit rejected material or stopped a release in the last year, and is that decision on paper (211.22)?

If you buy from any of the 18 recipients, add the letter to the supplier file and pull the facility's last Form 483. Repeat sections between that form and the letter are the best predictor of what FDA will check at re-inspection, and a repeat section on a facility with a prior letter is what FDA treats as a failed correction. The November edition of this tracker will start with the letters posted on November 3.

Atlas

FDA Inspection Intelligence Digest

We track every 483, EIR, and warning letter the moment it happens. Get the signals before they hit the FDA website.

Subscribe